Uncategorized

enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium

enVVeno Medical Corporation today announced that positive preliminary device related Material Adverse Event (MAE) safety data from the SAVVE U.S. pivotal trial for the VenoValve is being presented today at the 50th Annual VEITH symposium in New York.

enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium Read More »

Vertex & CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorization for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia.

Vertex & CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Read More »

Scroll to Top